De-escalation of perioperative systemic therapy for early breast cancer
Makiko Ono, 相良安昭, Toshiyuki Ishiba, Yukinori Ozaki et autres
jp, us, gb (code pays fourni par la source)
0 citations
Japanese Journal of Clinical Oncology
Hideo Shigematsu
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
152Publications signalées
1331Citations signalées
2Affiliations récentes
Les institutions déclarées
Les domaines associés
Breast Cancer Treatment StudiesEpilepsy research and treatmentBreast Lesions and CarcinomasCancer Treatment and PharmacologyHER2/EGFR in Cancer Research
Les publications récentes
Eribulin versus taxane as first-line chemotherapy combined with dual HER2 blockade in patients with HER2-positive locally advanced or metastatic breast cancer: final survival outcomes of the JBCRG-M06/EMERALD study
S. Saji, T. Yamashita, Junji Tsurutani, Y. Sagara et autres
jp (code pays fourni par la source)
0 citations
ESMO Open
Lactobacillus reuteri lozenges and chemotherapy-induced oral mucositis in breast cancer outpatients: an exploratory randomized controlled trial
Hiromi Nishi, Susumu Horikoshi, Shinsuke Sasada, Yuki Kuwabara et autres
jp (code pays fourni par la source)
0 citations
Scientific Reports
Interim Breast MRI for Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Early Breast Cancer
Eri Kato, Hideo Shigematsu, Ai Amioka, Shinsuke Sasada et autres
jp (code pays fourni par la source)
0 citations
European Journal of Breast Health
Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancer
Tsuguo Iwatani, Norikazu Masuda, Shigehira Saji, Takuhiro Yamaguchi et autres
jp (code pays fourni par la source)
0 citations
Breast Cancer
De-escalation of breast surgery for early stage breast cancer
Takeshi Murata, Tomomi Fujisawa, Fumikata Hara, Toshiyuki Ishiba et autres
jp, us, gb (code pays fourni par la source)
0 citations
Japanese Journal of Clinical Oncology
Correction: Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017
Kiyo Tanaka, Akihiko Shimomura, Makoto Ishitobi, Takashi Yamanaka et autres
jp (code pays fourni par la source)
0 citations
Breast Cancer
Exploratory analysis of prognostic value of ctDNA monitoring among advanced breast cancer with oligometastatic disease: An ancillary biomarker study of JCOG 2110 (JCOG2110A1).
Takahiro Kogawa, Noriko Mitome, Toshiyuki Ishiba, Ikuno Nishibuchi et autres
jp (code pays fourni par la source)
0 citations
Journal of Clinical Oncology
A randomized phase II study of pembrolizumab plus paclitaxel with or without bevacizumab in PD-L1–positive recurrent triple-negative breast cancer previously treated with perioperative immune checkpoint inhibitors: WJOG16522B (PRELUDE) trial.
Kazuki Nozawa, Yukinori Ozaki, Tomohiro Oshino, Kaori Terata et autres
jp (code pays fourni par la source)
0 citations
Journal of Clinical Oncology
Prediction of lymphocyte‐predominant breast cancer using microRNA expression in cytology specimens
Azusa Kai, Koji Arihiro, Hideo Shigematsu, Yukari Ohue‐Uchihata et autres
jp (code pays fourni par la source)
0 citations
Cancer Cytopathology
Primary tumour resection reduces the risk of major local morbidity in de novo stage IV breast cancer: secondary data analysis from the JCOG1017 randomized clinical trial
Makoto Ishitobi, Kiyo Tanaka, Akihiko Shimomura, Takashi Yamanaka et autres
ch, jp (code pays fourni par la source)
0 citations
British journal of surgery
Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017
Kiyo Tanaka, Akihiko Shimomura, Makoto Ishitobi, Takashi Yamanaka et autres
jp (code pays fourni par la source)
0 citations
Breast Cancer
BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.